All rights reserved. This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic mechanical, photocopying, recording or otherwise without the prior written permission of the publisher.

published: Nov’ 2013

China Diabetes Market Outlook 2018

Table of ConTenTs

5.1 Rising Prevalence of Obesity5.2 Increasing Investment from Global Giants5.3 Advancement in Insulin Pens Improving the Delivery Mechanism

6.1 Oral Diabetic Drugs Market 6.1.1 By Drugs6.2 Insulin Drugs Market 6.2.1 By Players

7.1 Insulin Pens7.2 Insulin Syringes

8.1 Self Monitoring Blood Glucose (SMBG) Devices

10.1 Novo Nordisk10.2 Eli Lilly10.3 Sanofi-Aventis10.4 Tonghua Dongbao Pharmaceutical Co. Ltd.10.5 Merck & Co.10.6 Tianjin Takeda Pharmaceuticals Co Ltd.10.7 Bayer10.8 Medtronic10.9 Terumo Corporation

1. Analyst View

2. Research Methodology

3. Patient Profile Analysis

4. Cost Implications

5. Market Drivers and Trends

6. Diabetes Drugs Market

7. Insulin Delivery Devices Market

8. Glucose Monitoring Devices Market

9. Government Regulations and Initiatives

10. Key Players

China Diabetes Market Outlook 2018

lisT of figures

China Diabetes Market Outlook 2018

Figure 3-1: Prevalence of Diabetes in Age Group 20-79 Years (%), 2012 & 2030Figure 3-2: Diabetic Population in Age Group 20-79 Years (Million), 2012 & 2030Figure 4-1: India & China - National Income Loss by Diabetes and Cardiovascular Diseases (Billion US$), 2005 to 2015Figure 6-1: Oral Diabetic Drugs Market (Billion US$), 2012-2018Figure 6-2: Insulin Drugs Market (Billion US$), 2012-2018Figure 6-3: Insulin Market Share by Player (2012)Figure 7-1: Insulin Delivery Device Market (Million US$), 2012-2018Figure 7-2: Insulin Pen Market (Million US$), 2012-2018Figure 7-3: Insulin Syringes Market (Million US$), 2012-2018Figure 8-1: SMBG Devices Market (Million US$), 2012-2018

China Diabetes Market Outlook 2018

Cost implications

sample Sections from the report

Diabetes, which is attaining the proportion of an epidem-ics, is one of the fastest-growing diseases in China, and it was estimated to have affected over xx Million people in 2012. There are diabetics around the world who are still undiagnosed. In few poorer nations, xx% to xx% of peo-ple with diabetes are undiagnosed; while even in high-income nations, xx% may be undiagnosed. In China, xx% adults with diabetes are undiagnosed. This is due to poor public awareness and limited opportunities for diagnosis.

Various studies have shown that diabetes involves high costs associated with its treatment, which poses a burden on the healthcare budget of the country. For example, the World Health Organization has estimated that India and China will correspondingly lose US$ xx Billion and US$ xx Billion of national incomes to diabetes and car-diovascular diseases during 2005-2015.The ailments may consume approximately more than half of the countries’ annual health budgets respectively.

In China, during 2012, the mean healthcare expenditure per person with diabetes was approximately US$ xx throughout the country. The diabetes prevalence was approximately xx%. This increasing prevalence has by now become an affliction. The World Health Organi-zation (WHO) estimates that diabetes linked chronic diseases will cost China US$ xx Billion in lost productivity and healthcare costs over the next decade.

Hence, it is clear that diabetes costs billions of dollars on the Chinese economy. The government should take im-portant steps to control the incidence rate of the disease. It should therefore establish medical institutions, which can provide healthcare services (such as drugs, tests for diabetes diagnosis) and treatment related to diabetes at lower costs. This would mean providing effective medical intervention, which will lower the costs incurred.

figure 4-1: india & China - national income loss by Diabetes and Cardiovascular Diseases (billion us$), 2005 to 2015

Source: xx

India China

China Diabetes Market Outlook 2018

Diabetes is one of the greatest worldwide health chal-lenges of the twenty-first century. It has been estimated that China accounted for around xx Million diabetic patients by the end of 2012. Despite advances in the disease’s treatment during the last two decades, the prevalence and incidence of diabetes are increasing at alarming rates.

Self-monitoring of blood glucose (SMBG) is a significant part of modern therapy for diabetes mellitus. SMBG has been suggested for people with diabetes and their health care professionals to gain a specific level of gly-cemic control and to prevent hypoglycemia. The objec-tive of SMBG is to gather complete information regard-ing patient’s blood glucose levels at various time points to allow maintenance of a more consistent glucose level through more specific routines. SMBG can be utilized to help adjust a therapeutic regimen in response to blood glucose values and to assist individuals in adjusting their dietary intake, physical activity, and insulin doses to enhance glycemic control on a regular basis.

With developments in technology, several research and clinical trials have allowed the development of newer and better SMBG devices that comprise various func-tions in one device such as energy consumption calcula-tor for numerous activities, food calorie tracker, alarm and blood pressure measurement. Such SMBG devices

are potentially preferred over strips. On account of the related benefits, the demand for SMBG devices has been surging across the globe. The same trend is being followed in China too and the market for SMBG devices was estimated to reach approximately US$ xx Million in 2012 and is forecasted to reach approximately US$ xx Million by end of 2018.

Several attempts undertaken by the government to increase the level of awareness regarding diabetes has propelled the sale of self-monitoring devices for better blood sugar control. Nevertheless, awareness in rural and sub-urban regions still remains low. Efforts are being directed towards propagating awareness in rural regions to efficiently control the prevalence of the disease and uplift prospects for the SMBG devices and strips market. Due to this, sale of blood glucose meters (BGM) and strips, needed for self-monitoring, through retail has increased during the past x years and has become a significant revenue stream for BGM device manufacturers.

Several painless glucose monitors are at clinical trials development phase and introduction of these devices with high-end features will help device manufacturers to stand out in the market. The devices are expected to be small and easy to use that shall make measuring glucose levels pain-free and non-invasive.

glucose Monitoring Devices Market

self Monitoring blood glucose (sMbg) Devices

figure 8-1: sMbg Devices Market (Million us$), 2012-2018

Source: RNCOS

The objective of SMBG is to gather complete infor-

mation regarding patient’s blood glucose levels at

various time points to allow maintenance of a more con-sistent glucose level through

more specific routines.2012e 2013e 2014f 2015f 2016f 2017f 2018f

China Diabetes Market Outlook 2018

research Methodology

RNCOS’ dedicated team of industry experts intensively monitored the diabetes market of all the emerging economies across the world. It found that diabetes has become a catastrophe among Chinese population thus providing immense growth opportunities to pharmaceutical players with diabetes product portfolios. This encouraged RNCOS to study the Chinese diabetes market and explore the market’s different growth opportunities. The present study is set to help RNCOS’ clients plan their investment decisions.

For the study, RNCOS gathered information from various credible sources and some of its paid databases, including Nexis Lexis, One Source etc. RNCOS also referred to books, white papers, trade journals, and industry portals to pro-vide authentic, reliable, and refined information. It also conducted expert interviews with industry players in China to validate its research findings.

RNCOS’ team of experts has prudently evaluated all the collected information and presented it in a chronological order to depict a meaningful and clear picture of the diabetes sector. It is worth mentioning that while compiling the data RNCOS’ experts also cross-checked all the collected information from other multiple sources and data warehouses so they could present a most accurate and precise information on the sector.

The forecasts provided are based on the sum of RNCOS’ economic and judgmental analyses of the past trends and drivers, challenges, and opportunities for expansion. Most importantly, while forecasting, RNCOS also gave due con-sideration to the key vertical sector demand and developments, which are essential in determining the prospective growth potentials of the sector. In this way, RNCOS’ report depicts the most unbiased picture of the Chinese diabetes market that will prove decisive for its clients.

China Diabetes Market Outlook 2018

License Type

Payment Options

Electronic Access - Single User License : US$ 1000.00

CD-ROM Mail Delivery - Single User License : US$ 1100.00

Hard Copy Mail Delivery - Single User License : US$ 1100.00

Electronic Access - Multi-User License - Single User License : US$ 1600.00

Pay by Credit Card

Pay by wire transfer

Bank Wire Transfer Details

All payments made using your credit card are processed by our Payment Gateway www.2checkout.com. On receipt of con-firmation that your payment has been credited to our account (generally takes 4 to 6 hours) we shall dispatch the electronic copy of the report to you.

This allows you to transfer money from your bank account to our account. Please allow 3-4 working days for processing of this order.

Account Name: RNCOS E Services Pvt. Ltd.A/C No: 1302125Swift Code: ABNAINBBDELName of Bank: The Royal Bank of Scotland N.VBank Address: Hansalaya Building,15, Barakhamba Road,New Delhi-110001India

Contact Information

B 129, Sector 6, Noida, IndiaPh.: + 91 (120) 4224700 Extn.

203/208Fax: + 91 (120) 4224707

Email: marketing@rncos.comWebsite: www.rncos.com

China Diabetes Market Outlook 2018

Established in 2002, RNCOS is a premier source of healthcare research and information provider. We bring first-hand informa-tion and prudent analysis on the healthcare industry, technologies, economic and non-economic market parameters, poten-tial markets, and key competitors, to help clients identify prospective growth areas and gain competitive edge.

All our research solutions are supported by robust, evidence-based analytics grounded by extensive primary and secondary research. They not only provide the most up-to-date market figures, forecasts, and pipeline data, but offers valuable insights on successes and failures in the ever-competitive healthcare industry.

Our reports provide strategic information for investment bankers, companies, management consultants, trade associations, corporate executives and business analysts. Our work helps them to support critical business decisions such as, entering new markets, launching and enhancing products, making acquisitions or strategic investments, unseating competitors and more.

about RNCOS

WORK PROCESS

The findings, conclusions and recommendations that RNCOS delivers are based on information gathered in good faith from both primary and secondary sources. Neither the company nor any of its employees makes any warranty, express or implied, including the warranties of merchantability and fitness for a particular purpose, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, elec-tronic, mechanical, photocopying, recording or otherwise, without the prior permission of RNCOS. Such protected material, however, may be used under the terms of “fair use” as defined in the copyright laws, which generally permits use for non-commercial educational purposes such as teaching, research, criticism, and news reporting.

Unless otherwise stated, the copyright, database rights, and other similar rights of this publication are solely owned by RN-COS.You are permitted to print or download extracts from this material for your personal use only. None of this material may be used for any commercial or public use.

No part of research material appearing may be reproduced, stored in or transmitted on any other Website without written permission of RNCOS and any payments of a specified fee. Requests to republish any material may be sent to us and it is our sole discretion to allow it or not.

Disclaimer